BioAtla Inc (BCAB) - שווי פעילות לרווח לפני ריבית, מסים ופחת
BioAtla, Inc. (BCAB) develops specific antibodies that activate exclusively within the acidic environment of neoplasms, protecting healthy cells from toxicity. This price action visualized on the GURU.Markets platform shows that the EV/EBITDA ratio is 0.00. The business relies on a closed R&D circuit with high barriers to entry; however, due to the lack of commercial products and its current trial stage, the company lacks a stable cash flow.
BCAB (bioatla.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The innovative platform of BioAtla, Inc. (BCAB) for creating activatable biologics and its patent authority determine the long-term business value, which is reflected on GURU.Markets by the company's historical EV/EBITDA trend. This ratio correlates the total market value of the asset with its operating profit before taxes and depreciation, allowing investors to assess the real value of the business accounting for debt and determine the asset's undervaluation relative to the sector.
